Business Description
Faron Pharmaceuticals Oy
ISIN : FI4000153309
Description
Financial Strength
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 2.36 | |||||
Equity-to-Asset | 0.04 | |||||
Debt-to-Equity | 9.22 | |||||
Debt-to-EBITDA | N/A | |||||
Interest Coverage | N/A | |||||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -4.9 | |||||
3-Year EPS without NRI Growth Rate | -7.4 | |||||
3-Year FCF Growth Rate | 3.2 | |||||
3-Year Book Growth Rate | -74 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate | 10.64 |
Momentum Rank
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 46.16 | |||||
9-Day RSI | 52.74 | |||||
14-Day RSI | 56.46 | |||||
6-1 Month Momentum % | 30.25 | |||||
12-1 Month Momentum % | -36.56 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.45 | |||||
Quick Ratio | 1.45 | |||||
Cash Ratio | 1.28 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -13.6 | |||||
Shareholder Yield % | 0.23 |
Profitability Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROA % | -286.54 | |||||
ROIC % | -398.75 | |||||
3-Year ROIIC % | -636.9 | |||||
ROC (Joel Greenblatt) % | -10779.13 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 200.91 | |||||
EV-to-EBIT | -8.52 | |||||
EV-to-Forward-EBIT | -3.73 | |||||
EV-to-EBITDA | -8.63 | |||||
EV-to-Forward-EBITDA | -8.75 | |||||
EV-to-Forward-Revenue | 768.72 | |||||
EV-to-FCF | -10.51 | |||||
Earnings Yield (Greenblatt) % | -11.72 | |||||
FCF Yield % | -9.12 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Faron Pharmaceuticals Oy Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | |||
EPS (TTM) (€) | -0.399 | ||
Beta | 1.96 | ||
Volatility % | 106.54 | ||
14-Day RSI | 56.46 | ||
14-Day ATR (€) | 0.08588 | ||
20-Day SMA (€) | 2.53375 | ||
12-1 Month Momentum % | -36.56 | ||
52-Week Range (€) | 1.038 - 3.481935 | ||
Shares Outstanding (Mil) | 104.62 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 2 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Faron Pharmaceuticals Oy Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Faron Pharmaceuticals Oy Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Faron Pharmaceuticals Oy Frequently Asked Questions
What is Faron Pharmaceuticals Oy(FRA:4FR)'s stock price today?
When is next earnings date of Faron Pharmaceuticals Oy(FRA:4FR)?
Does Faron Pharmaceuticals Oy(FRA:4FR) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |